These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6128543)

  • 41. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
    Kaisary A; Smith P; Jaczq E; McAllister CB; Wilkinson GR; Ray WA; Branch RA
    Cancer Res; 1987 Oct; 47(20):5488-93. PubMed ID: 3652049
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acetylation phenotypes in patients with bladder carcinoma.
    Bicho MP; Breitenfeld L; Carvalho AA; Manso CF
    Ann Genet; 1988; 31(3):167-71. PubMed ID: 3265609
    [TBL] [Abstract][Full Text] [Related]  

  • 43. N-acetyltransferase activity--a susceptibility factor in human bladder carcinogenesis.
    Dewan A; Chattopadhyay P; Kulkarni PK
    Indian J Cancer; 1995 Mar; 32(1):15-9. PubMed ID: 7558106
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction.
    Green J; Banks E; Berrington A; Darby S; Deo H; Newton R
    Br J Cancer; 2000 Aug; 83(3):412-7. PubMed ID: 10917561
    [TBL] [Abstract][Full Text] [Related]  

  • 45. N-acetyltransferase phenotype of patients with cancer of the larynx.
    Drózdz M; Gierek T; Jendryczko A; Pilch J; Piekarska J
    Neoplasma; 1987; 34(4):481-4. PubMed ID: 3658048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.
    Hein DW
    Oncogene; 2006 Mar; 25(11):1649-58. PubMed ID: 16550165
    [TBL] [Abstract][Full Text] [Related]  

  • 47. N-Acetyltransferase phenotypes in Iraqi and British population.
    Cartwright RA; Ahmad RA; Rogers HJ
    Hum Hered; 1984; 34(2):101-4. PubMed ID: 6745950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Occupational and non-occupational risk factors in bladder cancer patients in an industrialized area located in former East-Germany].
    Golka K; Seidel T; Dietrich H; Roth G; Rötzel C; Thier R; Geller F; Reckwitz T; Schulze H
    Aktuelle Urol; 2005 Sep; 36(5):417-22. PubMed ID: 16163604
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis.
    Kadlubar FF; Butler MA; Kaderlik KR; Chou HC; Lang NP
    Environ Health Perspect; 1992 Nov; 98():69-74. PubMed ID: 1486865
    [TBL] [Abstract][Full Text] [Related]  

  • 50. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk.
    Stern MC; Johnson LR; Bell DA; Taylor JA
    Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1004-11. PubMed ID: 12376500
    [TBL] [Abstract][Full Text] [Related]  

  • 51. N-acetyltransferase 1 polymorphism and bladder cancer susceptibility: a meta-analysis of epidemiological studies.
    Wu K; Wang X; Xie Z; Liu Z; Lu Y
    J Int Med Res; 2013 Feb; 41(1):31-7. PubMed ID: 23569127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis.
    Kim WJ; Lee HL; Lee SC; Kim YT; Kim H
    J Urol; 2000 Jul; 164(1):209-13. PubMed ID: 10840461
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study.
    Lubin JH; Kogevinas M; Silverman D; Malats N; Garcia-Closas M; Tardón A; Hein DW; Garcia-Closas R; Serra C; Dosemeci M; Carrato A; Rothman N
    Int J Epidemiol; 2007 Feb; 36(1):236-41. PubMed ID: 17510079
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer.
    Deitz AC; Rothman N; Rebbeck TR; Hayes RB; Chow WH; Zheng W; Hein DW; García-Closas M
    Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1543-6. PubMed ID: 15342459
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk.
    Millikan RC; Pittman GS; Newman B; Tse CK; Selmin O; Rockhill B; Savitz D; Moorman PG; Bell DA
    Cancer Epidemiol Biomarkers Prev; 1998 May; 7(5):371-8. PubMed ID: 9610785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Metabolic polymorphisms and the cancer risk: the evaluation of epidemiological studies].
    Vineis P; Landi MT; Caporaso N
    Med Lav; 1992; 83(6):557-75. PubMed ID: 1296137
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The association of the slow acetylator phenotype with bladder cancer.
    Evans DA; Eze LC; Whibley EJ
    J Med Genet; 1983 Oct; 20(5):330-3. PubMed ID: 6644762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NAT1 genotypic and phenotypic contribution to urinary bladder cancer risk: a systematic review and meta-analysis.
    Dhaini HR; El Hafi B; Khamis AM
    Drug Metab Rev; 2018 May; 50(2):208-219. PubMed ID: 29258340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of N-acetyltransferase-2 and glutathione S-transferase on the risk and aggressiveness of bladder cancer.
    Giannakopoulos X; Charalabopoulos K; Baltogiannis D; Chatzikiriakidou A; Alamanos Y; Georgiou I; Evangelou A; Agnantis N; Sofikitis N
    Anticancer Res; 2002; 22(6B):3801-4. PubMed ID: 12552997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation between N-acetyltransferase activities in uroepithelia and in vivo acetylator phenotype.
    Pink JC; Messing EM; Reznikoff CA; Bryan GT; Swaminathan S
    Drug Metab Dispos; 1992; 20(4):559-65. PubMed ID: 1356735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.